Analysts expect Flexion Therapeutics Inc (NASDAQ:FLXN) to announce earnings of ($1.06) per share for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Flexion Therapeutics’ earnings. The lowest EPS estimate is ($1.08) and the highest is ($1.04). Flexion Therapeutics posted earnings of ($1.16) per share in the same quarter last year, which would suggest a positive year over year growth rate of 8.6%. The firm is expected to report its next earnings report on Tuesday, August 6th.
On average, analysts expect that Flexion Therapeutics will report full-year earnings of ($4.07) per share for the current financial year, with EPS estimates ranging from ($4.18) to ($3.93). For the next financial year, analysts expect that the firm will post earnings of ($2.44) per share, with EPS estimates ranging from ($2.95) to ($1.68). Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Flexion Therapeutics.
Flexion Therapeutics (NASDAQ:FLXN) last posted its earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($1.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.04. Flexion Therapeutics had a negative return on equity of 131.94% and a negative net margin of 549.07%. The company had revenue of $10.56 million for the quarter, compared to the consensus estimate of $11.10 million.
In other Flexion Therapeutics news, insider Michael D. Clayman bought 4,012 shares of the firm’s stock in a transaction that occurred on Friday, May 10th. The shares were bought at an average price of $12.48 per share, with a total value of $50,069.76. Following the purchase, the insider now owns 74,868 shares of the company’s stock, valued at $934,352.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO David Arkowitz bought 4,000 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The shares were acquired at an average cost of $11.99 per share, for a total transaction of $47,960.00. Following the purchase, the chief financial officer now directly owns 86,924 shares in the company, valued at approximately $1,042,218.76. The disclosure for this purchase can be found here. Insiders bought 18,512 shares of company stock worth $226,775 in the last ninety days. Corporate insiders own 16.01% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the stock. Redmile Group LLC raised its position in shares of Flexion Therapeutics by 63.1% in the 1st quarter. Redmile Group LLC now owns 21,630 shares of the specialty pharmaceutical company’s stock worth $270,000 after acquiring an additional 8,370 shares in the last quarter. Gagnon Securities LLC grew its stake in Flexion Therapeutics by 171.2% during the 1st quarter. Gagnon Securities LLC now owns 688,271 shares of the specialty pharmaceutical company’s stock worth $8,590,000 after buying an additional 434,448 shares during the last quarter. Gagnon Advisors LLC grew its stake in Flexion Therapeutics by 89.6% during the 1st quarter. Gagnon Advisors LLC now owns 401,648 shares of the specialty pharmaceutical company’s stock worth $5,013,000 after buying an additional 189,860 shares during the last quarter. DekaBank Deutsche Girozentrale grew its stake in Flexion Therapeutics by 22.4% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 15,300 shares of the specialty pharmaceutical company’s stock worth $343,000 after buying an additional 2,800 shares during the last quarter. Finally, Claro Advisors LLC grew its stake in Flexion Therapeutics by 33.0% during the 1st quarter. Claro Advisors LLC now owns 22,150 shares of the specialty pharmaceutical company’s stock worth $276,000 after buying an additional 5,500 shares during the last quarter. 89.88% of the stock is currently owned by institutional investors.
FLXN stock traded up $0.48 during trading on Tuesday, reaching $12.10. The stock had a trading volume of 6,029 shares, compared to its average volume of 445,370. Flexion Therapeutics has a 52 week low of $9.65 and a 52 week high of $29.10. The firm’s 50 day moving average is $11.70. The company has a debt-to-equity ratio of 2.10, a quick ratio of 6.06 and a current ratio of 6.32. The company has a market capitalization of $457.59 million, a price-to-earnings ratio of -2.71 and a beta of 1.40.
About Flexion Therapeutics
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.
Recommended Story: What is a Real Estate Investment Trust (REIT)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.